DDInter1544 DDInter1576
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Regorafenib {u} (Compound) resembles {v} (Compound) Sorafenib
Regorafenib {u} (Compound) binds {v} (Gene) CYP2C9
Regorafenib {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Regorafenib {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Regorafenib (Compound) resembles Sorafenib (Compound)
Regorafenib (Compound) binds CYP2C9 (Gene)
Regorafenib (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Regorafenib (Compound) causes Myocardial infarction (Side Effect)
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Regorafenib may lead to a major life threatening interaction when taken with Fondaparinux
Regorafenib may lead to a major life threatening interaction when taken with Venetoclax